Hypnotherapy for smoking cessation.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
14 06 2019
Historique:
pubmed: 15 6 2019
medline: 10 9 2019
entrez: 15 6 2019
Statut: epublish

Résumé

Hypnotherapy is widely promoted as a method for aiding smoking cessation. It is intended to act on underlying impulses to weaken the desire to smoke, or strengthen the will to stop. To evaluate the effect and safety of hypnotherapy for smoking cessation. For this update we searched the Cochrane Tobacco Addiction Group Specialized Register, and trial registries (ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform), using the terms "smoking cessation" and "hypnotherapy" or "hypnosis", with no restrictions on language or publication date. The most recent search was performed on 18 July 2018. We considered randomized controlled trials that recruited people who smoked and implemented a hypnotherapy intervention for smoking cessation compared with no treatment, or with any other therapeutic interventions. Trials were required to report smoking cessation rates at least six months after the beginning of treatment. Study eligibility was determined by at least two review authors, independently. At least two review authors independently extracted data on participant characteristics, the type and duration of hypnotherapy, the nature of the control group, smoking status, method of randomization, and completeness of follow-up. These authors also independently assessed the quality of the included studies. In undertaking this work, we used standard methodological procedures expected by Cochrane.The main outcome measure was abstinence from smoking after at least six months' follow-up. We used the most rigorous definition of abstinence in each trial, and biochemically validated abstinence rates where available. Those lost to follow-up were considered to still be smoking. We summarized effects as risk ratios (RRs) and 95% confidence intervals (CIs). Where possible, we performed meta-analysis using a fixed-effect model. We also noted any adverse events reported. We included three new trials in this update, which brings the total to 14 included studies that compared hypnotherapy with 22 different control interventions. The studies included a total of 1926 participants. Studies were diverse and a single meta-analysis was not possible. We judged only one study to be at low risk of bias overall; we judged 10 studies to be at high risk of bias and three at unclear risk. Studies did not provide reliable evidence of a greater benefit from hypnotherapy compared with other interventions or no treatment for smoking cessation. Most individual studies did not find statistically significant differences in quit rates after six months or longer, and studies that did detect differences typically had methodological limitations.Pooling small groups of relatively comparable studies did not provide reliable evidence for a specific effect of hypnotherapy relative to controls. There was low certainty evidence, limited by imprecision and risk of bias, that showed no statistically significant difference between hypnotherapy and attention-matched behavioural treatments (RR 1.21, 95% CI 0.91 to 1.61; I There is insufficient evidence to determine whether hypnotherapy is more effective for smoking cessation than other forms of behavioural support or unassisted quitting. If a benefit is present, current evidence suggests the benefit is small at most. There is very little evidence on whether hypnotherapy causes adverse effects, but the existing data show no evidence that it does. Further large, high-quality randomized controlled trials, and more comprehensive assessments of safety, are needed on this topic.

Sections du résumé

BACKGROUND
Hypnotherapy is widely promoted as a method for aiding smoking cessation. It is intended to act on underlying impulses to weaken the desire to smoke, or strengthen the will to stop.
OBJECTIVES
To evaluate the effect and safety of hypnotherapy for smoking cessation.
SEARCH METHODS
For this update we searched the Cochrane Tobacco Addiction Group Specialized Register, and trial registries (ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform), using the terms "smoking cessation" and "hypnotherapy" or "hypnosis", with no restrictions on language or publication date. The most recent search was performed on 18 July 2018.
SELECTION CRITERIA
We considered randomized controlled trials that recruited people who smoked and implemented a hypnotherapy intervention for smoking cessation compared with no treatment, or with any other therapeutic interventions. Trials were required to report smoking cessation rates at least six months after the beginning of treatment. Study eligibility was determined by at least two review authors, independently.
DATA COLLECTION AND ANALYSIS
At least two review authors independently extracted data on participant characteristics, the type and duration of hypnotherapy, the nature of the control group, smoking status, method of randomization, and completeness of follow-up. These authors also independently assessed the quality of the included studies. In undertaking this work, we used standard methodological procedures expected by Cochrane.The main outcome measure was abstinence from smoking after at least six months' follow-up. We used the most rigorous definition of abstinence in each trial, and biochemically validated abstinence rates where available. Those lost to follow-up were considered to still be smoking. We summarized effects as risk ratios (RRs) and 95% confidence intervals (CIs). Where possible, we performed meta-analysis using a fixed-effect model. We also noted any adverse events reported.
MAIN RESULTS
We included three new trials in this update, which brings the total to 14 included studies that compared hypnotherapy with 22 different control interventions. The studies included a total of 1926 participants. Studies were diverse and a single meta-analysis was not possible. We judged only one study to be at low risk of bias overall; we judged 10 studies to be at high risk of bias and three at unclear risk. Studies did not provide reliable evidence of a greater benefit from hypnotherapy compared with other interventions or no treatment for smoking cessation. Most individual studies did not find statistically significant differences in quit rates after six months or longer, and studies that did detect differences typically had methodological limitations.Pooling small groups of relatively comparable studies did not provide reliable evidence for a specific effect of hypnotherapy relative to controls. There was low certainty evidence, limited by imprecision and risk of bias, that showed no statistically significant difference between hypnotherapy and attention-matched behavioural treatments (RR 1.21, 95% CI 0.91 to 1.61; I
AUTHORS' CONCLUSIONS
There is insufficient evidence to determine whether hypnotherapy is more effective for smoking cessation than other forms of behavioural support or unassisted quitting. If a benefit is present, current evidence suggests the benefit is small at most. There is very little evidence on whether hypnotherapy causes adverse effects, but the existing data show no evidence that it does. Further large, high-quality randomized controlled trials, and more comprehensive assessments of safety, are needed on this topic.

Identifiants

pubmed: 31198991
doi: 10.1002/14651858.CD001008.pub3
pmc: PMC6568235
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD001008

Subventions

Organisme : Department of Health
ID : SRP/16/114/20
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : UpdateOf

Références

Cochrane Database Syst Rev. 2000;(2):CD001008
pubmed: 10796583
Int J Clin Exp Hypn. 2000 Oct;48(4):374-87
pubmed: 11011498
J Clin Psychol. 1975 Jul;31(3):498-505
pubmed: 1165278
J Consult Clin Psychol. 1975 Dec;43(6):920
pubmed: 1194487
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Int J Clin Exp Hypn. 2006 Apr;54(2):224-33
pubmed: 16581692
Int J Clin Exp Hypn. 2006 Jul;54(3):303-15
pubmed: 16766441
Nicotine Tob Res. 2006 Dec;8(6):767-71
pubmed: 17132524
Nicotine Tob Res. 2008 May;10(5):811-8
pubmed: 18569754
West J Emerg Med. 2007 Aug;8(3):79-83
pubmed: 19561688
Br J Hosp Med. 1991 Jan;45(1):27-9
pubmed: 2009436
Am J Clin Hypn. 2010 Jan;52(3):167
pubmed: 20187332
Am J Clin Hypn. 2010 Jan;52(3):173-5
pubmed: 20187335
Cochrane Database Syst Rev. 2010 Oct 06;(10):CD001008
pubmed: 20927723
BMC Public Health. 2012 Apr 04;12:271
pubmed: 22475087
Am J Med. 2012 Jun;125(6):576-84
pubmed: 22502956
Int J Clin Exp Hypn. 2013;61(2):146-61
pubmed: 23427839
BMC Public Health. 2013 Dec 23;13:1227
pubmed: 24365274
Complement Ther Med. 2014 Feb;22(1):1-8
pubmed: 24559809
Health Technol Assess. 2015 Mar;19(25):1-148, v-vi
pubmed: 25827850
BMJ Open. 2015 Apr 17;5(4):e006959
pubmed: 25888475
Prev Med. 2016 Apr;85:20-31
pubmed: 26743631
Cochrane Database Syst Rev. 2017 Mar 31;3:CD001007
pubmed: 28361497
Am J Clin Hypn. 2017 Oct;60(2):159-171
pubmed: 28891777
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
J R Soc Med. 1988 Dec;81(12):701-4
pubmed: 3065498
Cochrane Database Syst Rev. 2019 Feb 13;2:CD003999
pubmed: 30758045
Addict Behav. 1988;13(2):205-8
pubmed: 3369332
Addict Behav. 1986;11(1):59-62
pubmed: 3716918
J Behav Med. 1986 Oct;9(5):475-89
pubmed: 3795265
Addict Behav. 1986;11(4):355-65
pubmed: 3812046
J Fam Pract. 1986 Jan;22(1):61-5
pubmed: 3941301
Int J Clin Exp Hypn. 1979 Jan;27(1):14-20
pubmed: 396255
J Abnorm Psychol. 1979 Oct;88(5):592-603
pubmed: 500967
Int J Clin Exp Hypn. 1970 Oct;18(4):235-50
pubmed: 5457608
Am J Clin Hypn. 1968 Jan;10(3):194-7
pubmed: 5641836
South Med J. 1968 Sep;61(9):999-1002
pubmed: 5676589
J Clin Psychol. 1983 Mar;39(2):198-202
pubmed: 6341410
Addict Behav. 1984;9(2):157-73
pubmed: 6377845
Am J Clin Hypn. 1978 Jul;21(1):45-7
pubmed: 696663
Addict Behav. 1980;5(1):41-7
pubmed: 6994434
Int J Clin Exp Hypn. 1980 Oct;28(4):341-57
pubmed: 6997219
Am J Clin Hypn. 1982 Oct-1983 Jan;25(2-3):104-13
pubmed: 7186768
J Indiana State Med Assoc. 1978 Dec;71(12):1136-7
pubmed: 722107
J Okla State Med Assoc. 1981 Mar;74(3):65-70
pubmed: 7277062
Psychol Rep. 1980 Jun;46(3 Pt 1):895-9
pubmed: 7394104
Int J Addict. 1980 Jul;15(5):615-29
pubmed: 7419297
Psychol Rep. 1994 Oct;75(2):851-7
pubmed: 7862796
Am J Psychiatry. 1993 Jul;150(7):1090-7
pubmed: 8317582
Int J Clin Exp Hypn. 1977 Jan;25(1):7-17
pubmed: 832925
Addict Behav. 1996 Jan-Feb;21(1):29-35
pubmed: 8729705

Auteurs

Joanne Barnes (J)

School of Pharmacy, University of Auckland, Private Bag 92019, Grafton Campus, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH